Abstract:Primary biliary cholangitis (PBC) is an archetypal autoimmune disease. Chronic lymphocytic cholangitis is associated with interface hepatitis, ductopenia, cholestasis, and progressive biliary fibrosis. People living with PBC are frequently symptomatic, experiencing a quality-of-life burden dominated by fatigue, itch, abdominal pain, and sicca complex. Although the female predominance, specific serum autoantibodies, immune-mediated cellular injury, as well as genetic (HLA and non-HLA) risk factors, identify PBC as autoimmune, to date treatment has focused on cholestatic consequences. Biliary epithelial homeostasis is abnormal and contributes to disease. The impact of cholangiocyte senescence, apoptosis, and impaired bicarbonate secretion enhances chronic inflammation and bile acid retention. First-line therapy is a non-specific anti-cholestatic agent, ursodeoxycholic acid. For those with residual cholestasis biochemically, obeticholic acid is introduced, and this semisynthetic farnesoid X receptor agonist adds choleretic, anti-fibrotic, and anti-inflammatory activity. Future PBC licensed therapy will likely include peroxisome proliferator activated receptor (PPAR) pathway agonists, including specific PPAR-delta agonism (seladelpar), as well as elafibrinor and saroglitazar (both with broader PPAR agonism). These agents dovetail the clinical and trial experience for off-label bezafibrate and fenofibrate use. Symptom management is essential, and encouragingly, PPAR agonists reduce itch; IBAT inhibition (eg, linerixibat) also appears promising for pruritus. For those where liver fibrosis is the target, NOX inhibition is being evaluated. Earlier stage therapies in development include therapy to impact immunoregulation in patients, as well other approaches to treating pruritus (eg, antagonists of MrgprX4). Collectively the PBC therapeutic landscape is exciting. Therapy goals are increasingly proactive and individualized and aspire to rapidly achieve normal serum tests and quality of life with prevention of end-stage liver disease.

Research Advances in Animal Models of Primary Biliary Cholangitis

The Pathogenesis, Models and Therapeutic Advances of Primary Biliary Cholangitis

Animal Models of Primary Biliary Cirrhosis

A Mouse Model Of Autoimmune Cholangitis Via Syngeneic Bile Duct Protein Immunization

Patient-derived Xenograft Models in Hepatopancreatobiliary Cancer

Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products

Research progress on primary biliary cirrhosis

Advances in diagnosis and treatment of primary biliary cholangitis

The Proinflammatory Cytokines IL-18, IL-21, and IFN-γ Differentially Regulate Liver Inflammation and Anti-Mitochondrial Antibody Level in a Murine Model of Primary Biliary Cholangitis

Primary biliary cholangitis: opportunities and challenges

Establishment of a mouse model of early primary biliary cirrhosis by polyinosinic-polycytidylic acid

Single-Cell Characterization of Hepatic CD8+ T Cells in a Murine Model of Primary Biliary Cholangitis

Effect of Allogeneic Bone Marrow–derived Mesenchymal Stem Cells Transplantation in a Polyi:C-Induced Primary Biliary Cirrhosis Mouse Model

Progress in the study of autoimmune antibodies in primary biliary cirrhosis

Experimental Evidence on the Immunopathogenesis of Primary Biliary Cirrhosis

Advances in the Treatment of Primary Biliary Cholangitis

Zebrafish Ppp1r21 Mutant As a Model for the Study of Primary Biliary Cholangitis

Dysregulation of Peritoneal Cavity B1a Cells and Murine Primary Biliary Cholangitis

Immunological Pathogenesis of Primary Biliary Cholangitis

Animal Models of Autoimmune Liver Diseases: a Comprehensive Review

New Treatment Paradigms in Primary Biliary Cholangitis